DrugPatentWatch Database Preview

Pfizer Company Profile

« Back to Dashboard

What is the competitive landscape for PFIZER, and what generic alternatives to PFIZER drugs are available?

PFIZER has one hundred and fifty-three approved drugs.

There are fifty-four US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.

There are one thousand four hundred and one patent family members on PFIZER drugs in seventy-nine countries and one hundred and fifty-eight supplementary protection certificates in fourteen countries.

Summary for Pfizer

International Patents:	1401
US Patents:	54
Tradenames:	120
Ingredients:	106
NDAs:	153
Drug Master File Entries:	3
Patent Litigation for Pfizer:	See patent lawsuits for Pfizer
PTAB Cases with Pfizer as petitioner:	See PTAB cases with Pfizer as petitioner

Drugs and US Patents for Pfizer

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	STREPTOMYCIN SULFATE	streptomycin sulfate	INJECTABLE;INJECTION	060111-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Pfizer	DARICON	oxyphencyclimine hydrochloride	TABLET;ORAL	011612-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Pfizer	SINEQUAN	doxepin hydrochloride	CONCENTRATE;ORAL	017516-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Pfizer	UNASYN	ampicillin sodium; sulbactam sodium	INJECTABLE;INJECTION	050608-002	Dec 31, 1986	AP	RX	Yes	Yes
Pfizer Pharms	ACCURETIC	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	020125-003	Dec 28, 1999	AB	RX	Yes	Yes

Expired US Patents for Pfizer

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-002	Dec 30, 1991	4,962,128*PED
Pfizer	GEODON	ziprasidone hydrochloride	CAPSULE;ORAL	020825-003	Feb 5, 2001	5,312,925
Pfizer Pharms	REZULIN	troglitazone	TABLET;ORAL	020720-001	Jan 29, 1997	5,478,852
Pfizer	FELDENE	piroxicam	CAPSULE;ORAL	018147-002	Apr 6, 1982	3,674,876
Pfizer	CADUET	amlodipine besylate; atorvastatin calcium	TABLET;ORAL	021540-011	Jul 29, 2004	6,455,574

Paragraph IV (Patent) Challenges for PFIZER drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Tablets	82.5 mg and 165 mg		2018-02-02
	Capsules	200 mg/30 mg		2004-12-27
	Tablets	25 mg and 50 mg		2004-11-19
	Capsules	20 mg, 40 mg, 60 mg and 80 mg		2005-02-07
	Tablets	20 mg and 40 mg		2010-03-29
	Capsules	0.125 mg, 0.25 mg, and 0.5 mg		2014-05-01
	Sublingual Tablets	0.6 mg		2011-12-29
	Tablets	150 mg and 200 mg		2005-11-09
	Tablets	5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg and 10 mg/80 mg		2006-12-29
	Tablets	2.5 mg/40 mg		2009-09-17
	Extended-release Tablets	330 mg		2018-01-29
	Extended-release Tablets	330 mg		2018-01-29
	Extended-release Tablets	11 mg		2016-11-07
	Capsules	200 mg/38 mg		2016-02-16
	Tablets	100 mg		2004-10-25
	Capsules	5 mg and 10 mg		2005-06-21
	Sublingual Tablets	0.3 mg, 0.4 mg and 0.6 mg		2005-10-19
	For Injection	500 mg/vial		2011-06-17
	Extended-release Tablets	4 mg and 8 mg		2012-10-31
	Tablets	5 mg/80 mg		2009-04-07
	Injection	20 mg/mL, 2 mL and 5 mL vials		2004-07-26
	Extended-release Tablets	82.5 mg and 165 mg		2018-02-02

Premature patent expirations for PFIZER

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

Non-Orange Book US Patents for Pfizer

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
6,231,851	Methods and compositions for the dry powder formulation of interferons
5,847,151	Gaba and L-glutamic acid analogs for antiseizure treatment
7,951,557	Human lysosomal proteins from plant cell culture
8,685,444	Sequestering subunit and related compositions and methods
8,883,217	Modified release formulations containing drug-ion exchange resin complexes

International Patents for Pfizer Drugs

Country	Document Number	Estimated Expiration
Estonia	200100221
Australia	2017202955
South Africa	200404840
Peru	06322000
Egypt	22154

Supplementary Protection Certificates for Pfizer Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2107069/01	Switzerland		PRODUCT NAME: INSULIN DEGLUDEC; REGISTRATION NO/DATE: SWISSMEDIC 62563 12.03.2013
2/2005	Austria		PRODUCT NAME: INSULIN GLULISINE
2017013	Lithuania		PRODUCT NAME: PALBOCIKLIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS, ESTERIO, AMIDO ARBA PROVAISTO PAVIDALU; REGISTRATION NO/DATE: EU/1/16/1147 20161109
2017025	Lithuania		PRODUCT NAME: TOFACITINIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS PAVIDALE, ISKAITANT CITRATO DRUSKAAA; REGISTRATION NO/DATE: EU/1/17/1178 20170322
13/034	Ireland		APPLICATION FOR EXTENSION OF THE DURATION OF A SUPPLEMENTARY PROTECTION CERTIFICATE 2013/034 IN JOURNAL NO. 2325 OF 25/01/2017 UNDER THE HEADING APPLICATION FOR EXTENSION OF THE DURATION OF A SUPPLEMENTARY PROTECTION CERTIFICATE, SPC NO. 2013/034 SHOULD HAVE APPEARED AS FOLLOWS, NOVO NORDISK A/S NOVO ALLE, 2880 BAGSVAERD, DENMARK (20/12/2016) PATENT NO: EP2107069; NOVEL INSULIN DERIVATIVES PRODUCT: INSULIN DEGLUDEC MARKET AUTHORISATION: EU: EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 (21/01/2013) ORIGINAL SPC EXPIRY DATE: 22/01/2028 1127 DESIGNS REGISTERED UNDER THE INDUSTRIAL DESIGNS ACT, 2001

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Pfizer
• Pfizer Cons Hlthcare
• Pfizer Global
• Pfizer Inc
• Pfizer Ireland